Sotatercept and the Activin Pathway: Beyond Myostatin

The muscle drug that grew up to save lungs. Sotatercept was originally developed as part of the same Acceleron family as ACE-031, designed to trap activin-family ligands and grow muscle.

It ended up doing something else entirely. As Winrevair, sotatercept is now the first activin-signaling inhibitor approved for pulmonary arterial hypertension, a once-fatal disease where it cuts mortality risk by 76% in high-risk patients.

Why a muscle pathway treats a lung disease

The surprise that built the drug. Pulmonary arterial hypertension is a disease of the small pulmonary arteries: the vessels narrow, thicken, and remodel, the right heart works harder to push blood through, and eventually it fails.

For decades, PAH treatment was about vasodilation. Endothelin antagonists, phosphodiesterase-5 inhibitors, and prostacyclin pathway drugs all open the vessels by acting on smooth muscle. They help, but they do not stop the underlying cell proliferation.

The activin axis turned out to be the missing piece. In healthy pulmonary arteries, BMP signaling restrains cell growth and activin signaling promotes it. The balance keeps the vessels stable.

In PAH patients, that balance flips. BMP signaling weakens (often through BMPR2 mutations or other genetic and acquired hits), and activin signaling dominates, which drives the smooth muscle cell proliferation that closes off the vessels.

Sotatercept reverses the balance. By trapping activin and GDF-11 before they reach the cell surface, it lets BMP signaling reassert control, and the vascular remodeling slows or reverses.

That was not obvious from the molecule's origin story.

How sotatercept actually works

It is a fusion protein, not an antibody. Sotatercept is built from the extracellular domain of activin receptor type IIA (ActRIIA) fused to the Fc domain of human IgG1.

The structure functions as a soluble decoy. Activin A, activin B, and GDF-11 normally bind ActRIIA on the cell membrane to trigger TGF-β superfamily signaling. With sotatercept circulating in the bloodstream, those ligands bind the trap and never reach the cell.

In the pulmonary artery, this restores the BMP-versus-activin balance. In the kidney and elsewhere, the same mechanism can raise red blood cell production by reducing GDF-11 suppression of erythropoiesis, which is where the hemoglobin side effect comes from.

For the molecular family context, see myostatin protein and the anti-myostatin antibody overview.

STELLAR Phase 3 results

The trial that won the approval. STELLAR enrolled 323 adults with PAH (WHO Group 1, functional class II or III) at 126 sites in 21 countries. Patients were already on background PAH therapy when they joined.

STELLAR was the basis for the FDA approval on March 26, 2024. The European Commission followed in August 2024.

The 41-meter walk distance gain is enormous for a PAH drug added on top of existing therapy. Most newer PAH agents have struggled to show double-digit improvements on top of established background.

ZENITH and the mortality story

The next trial pushed harder. ZENITH enrolled 172 adult PAH patients at high risk of mortality and tested sotatercept on top of standard therapy.

The trial was stopped early. An independent data monitoring committee called the study at an interim analysis because of a 76% reduction in major morbidity and mortality events (hazard ratio 0.24, 95% CI 0.13 to 0.43, p<0.0001).

Primary endpoint events occurred in 17% of sotatercept patients versus 55% of placebo. That is one of the strongest mortality signals seen in any PAH trial.

The FDA expanded the Winrevair label on October 27, 2025 based on ZENITH, formally recognizing the mortality benefit in the indication language.

CADENCE in HFpEF and CpcPH

The third trial answered a different question. CADENCE looked at patients with heart failure with preserved ejection fraction (HFpEF) and severe combined post- and pre-capillary pulmonary hypertension (CpcPH), a much larger population than classical PAH.

The trial enrolled 164 patients (mean age 75, 70% women) and randomized them to sotatercept 0.3 mg/kg, sotatercept 0.7 mg/kg, or placebo every 3 weeks.

At 24 weeks, median pulmonary vascular resistance dropped by 0.67 Wood units at 0.3 mg/kg (p=0.004) and 0.33 Wood units at 0.7 mg/kg (p=0.024) versus a 0.26 Wood unit rise on placebo.

Mean pulmonary artery pressure fell about 9 mmHg in both treatment arms, and pulmonary arterial wedge pressure fell about 3 mmHg.

Results were presented at ACC.26 in March 2026 and published simultaneously in Circulation. This was the first proof of concept that activin-signaling inhibition could help patients with the much more common HFpEF-related pulmonary hypertension, not just classical PAH.

How sotatercept is dosed

This is not a peptide-vendor protocol. Sotatercept dosing in PAH is precise.

Each injection is given subcutaneously, usually in the abdomen or thigh, by a healthcare professional initially with patient self-administration possible after training.

The 3-week dosing interval reflects the long half-life of the Fc-fusion structure. Patients on Winrevair do not need daily or weekly injections.

Side effects and why hemoglobin rises

The activin pathway has a kidney side. Common adverse events in STELLAR (occurring in 10% or more of Winrevair patients and at least 5% more than placebo) were headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, and erythema.

The hemoglobin rise is mechanism-driven. GDF-11 normally suppresses erythropoiesis, and trapping it with sotatercept removes that brake. Hemoglobin levels can climb meaningfully, which raises the risk of thromboembolic events if not monitored.

Serious bleeding occurred in 4% of Winrevair patients versus 1% of placebo. That signal is why the label requires hemoglobin and platelet monitoring before each of the first 5 doses, with dose adjustments built in.

Telangiectasia and epistaxis show up here for the same reason they showed up with ACE-031: the BMP/activin axis affects vascular endothelium when you tilt it. Sotatercept tilts it less than ACE-031 did, but the echo is still there.

Why sotatercept is not a muscle-building drug

This is where the internet gets confused. Because sotatercept came from the same Acceleron platform as ACE-031 and traps activin-family ligands, online discussions sometimes frame it as a muscle-building drug.

It is not. Here is why.

1. The dose is too low for muscle effects. Sotatercept's 0.3 to 0.7 mg/kg every 3 weeks is roughly 5 to 10 times lower than ACE-031's muscle-effective dose.
2. The receptor is different. Sotatercept uses ActRIIA, not ActRIIB. The two receptors overlap in some ligands but differ in their relative affinity for myostatin specifically.
3. Myostatin has higher affinity for ActRIIB than ActRIIA. That is why luspatercept (the chimeric ActRIIB-Fc variant) was developed for anemia in MDS, not for muscle.
4. The clinical signal in muscle was modest. Phase 1 work showed small lean-mass changes, but Acceleron and then Merck never pursued sotatercept as a muscle drug.
5. The safety profile in PAH is built around low doses. Higher doses would amplify hemoglobin rises and bleeding risk without a clear muscle-building case.

Sotatercept is also formally indicated only for PAH, and the cost (roughly $14,000 per vial, around $240,000 per year list price) is not how anyone responsibly chases muscle gain.

For the actual myostatin drug landscape, see apitegromab, bimagrumab, and the best myostatin inhibitor overview.

How sotatercept compares to its activin siblings

The family tree explains the indications.

Sotatercept is the only one of these that became a major cardiology drug, and the only one whose target organ is the lung, not the muscle, skeleton, or hematopoietic system.

What costs and access look like

The price is significant. Winrevair's US list price is approximately $14,000 per vial, with annual costs around $240,000 per patient depending on weight and dose level.

Coverage typically requires specialty pharmacy distribution, prior authorization for PAH WHO Group 1 with functional class II or III, and documentation of background PAH therapy. Most commercial insurers and Medicare cover it under medical benefit for PAH centers of excellence.

The ZENITH-driven label expansion in 2025 broadened access for high-risk PAH patients but did not change the core PAH-only restriction.

What is still unknown

The big open questions.

• Whether sotatercept reverses pulmonary vascular remodeling on imaging, not just hemodynamics
• Long-term outcomes beyond the trial period, especially around right ventricular recovery
• How sotatercept performs in pediatric PAH (trials ongoing)
• Whether HFpEF-CpcPH becomes a formal label expansion after CADENCE
• Long-term thromboembolic risk with sustained hemoglobin elevation
• Whether sotatercept has a role in scleroderma-associated PAH or chronic thromboembolic disease

The drug's biology is broader than its current indication, and Merck has not been quiet about exploring more.

Sources and notes

This article was built from DuckDuckGo and Bing SERP review, full-page competitor reads, and primary sources:

• Sotatercept Wikipedia entry
• STELLAR Phase 3 trial, NEJM 2023
• Merck Winrevair FDA approval announcement
• Pharmacy Times: FDA expands sotatercept approval after ZENITH
• CADENCE trial results at ACC.26
• Clinical review of sotatercept on NCBI Bookshelf
• Mayo Clinic sotatercept-csrk monograph
• Drugs.com sotatercept side effects
• VA national drug monograph for Winrevair

Frequently Asked Questions